UCB

OverviewSuggest Edit

UCB is a biopharma company, focusing on neurology and immunology. It develops products for the treatment of epilepsy, Parkinson's disease, restless legs syndrome, ankylosing spondylitis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis.
TypePublic
Founded1928
HQAnderlecht, BE
Websiteucb.com
Employee Ratings4
Overall CultureD

Latest Updates

Employees (est.) (Apr 2022)7,600(-5%)
Job Openings410
Revenue (FY, 2021)€5.5 B(+9%)
Share Price (May 2022)€88(-13%)
Cybersecurity ratingDMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at UCB

Jean-Christophe Tellier

Jean-Christophe Tellier

Chief Executive Officer & Chairman of the Executive Committee
Kirsten Lund-Jurgensen

Kirsten Lund-Jurgensen

Executive Vice President of Supply & Technology Solutions
Dhavalkumar Patel

Dhavalkumar Patel

Executive Vice President & Chief Scientific Officer
Emmanuel Caeymaex

Emmanuel Caeymaex

Executive Vice President of Immunology Solutions & Head of US
Jean-Luc Fleurial

Jean-Luc Fleurial

Executive Vice President & Chief Human Resources Officer
Iris Low-Friedrich

Iris Low-Friedrich

Executive Vice President & Chief Medical Officer
Show more

UCB Office Locations

UCB has offices in Anderlecht, Braine-l'Alleud, Raleigh, Smyrna and in 36 other locations
Anderlecht, BE (HQ)
60 Allée de la Recherche
Braine-l'Alleud, BE
Chemin du Foriest
Malvern, AU
Level 1/1155 Malvern Rd
Wien, AT
Twin Tower Wienerbergstrasse 11/12a
São Paulo, BR
Av. Presidente Juscelino Kubitschek, n° 1.327, 5° andar, Condominio Edificio Intemacional Plaza II
Sofia, BG
2B Srebarna street, fl. 9, office 8B
Show all (40)

UCB Financials and Metrics

UCB Revenue

UCB's revenue was reported to be €5.47 b in FY, 2021
EUR

Revenue (FY, 2021)

5.5b

Gross profit (FY, 2021)

4.8b

Net income (FY, 2021)

1.1b

EBITDA (FY, 2021)

1.6b

EBIT (FY, 2021)

1.3b

Market capitalization (13-May-2022)

16.6b

Closing stock price (13-May-2022)

88.0

Cash (31-Dec-2021)

1.3b

EV

17.5b
UCB's current market capitalization is €16.6 b.
Annual
EURFY, 2018FY, 2019FY, 2020FY, 2021

Revenue

4.4b4.7b5.1b5.5b

Cost of goods sold

(911.0m)(955.0m)(1.0b)(1.1b)

Gross profit

3.8b4.0b4.5b4.8b

R&D expense

(1.2b)(1.3b)(1.6b)(1.6b)
Half Year
EURH1, 2019H1, 2020H1, 2021

Revenue

2.2b2.5b2.7b

Cost of goods sold

(446.0m)(511.0m)(526.0m)

Gross profit

1.9b2.1b2.3b

R&D expense

(568.0m)(689.0m)(753.0m)
Annual
EURFY, 2018FY, 2019FY, 2020FY, 2021

Cash

1.3b1.3b1.3b1.3b

Accounts Receivable

616.0m686.0m742.0m887.0m

Prepaid Expenses

219.0m228.0m226.0m249.0m

Inventories

647.0m780.0m854.0m878.0m
Half Year
EURH1, 2019H1, 2020H1, 2021

Cash

1.0b968.0m568.0m

Accounts Receivable

940.0m1.1b1.2b

Prepaid Expenses

50.0m31.0m65.0m

Inventories

706.0m825.0m894.0m
Annual
EURFY, 2018FY, 2019FY, 2020FY, 2021

Net Income

800.0m792.0m732.0m1.1b

Depreciation and Amortization

288.0m313.0m354.0m283.0m

Inventories

(53.0m)(134.0m)(74.0m)(24.0m)

Accounts Payable

69.0m60.0m258.0m
Half Year
EURH1, 2019H1, 2020H1, 2021

Net Income

411.0m363.0m571.0m

Depreciation and Amortization

152.0m172.0m168.0m

Inventories

(59.0m)(45.0m)(40.0m)

Accounts Payable

(69.0m)106.0m(56.0m)
EURFY, 2018

Revenue/Employee

632.7k
Show all financial metrics

UCB Operating Metrics

FY, 2018H1, 2019FY, 2019H1, 2020FY, 2020

Patients Reached

3.3 m3.34 m3.5 m3.4 m3.5 m

Projects in Pipeline

10712

Countries

35

Locations (Research and Development)

12

UCB Acquisitions / Subsidiaries

Company NameDateDeal Size
Ra PharmaceuticalsApril 02, 2020$2.3 b
Alden Health, Inc.
Beryllium Discovery Corp.
Celltech Group Ltd
Celltech R&D Ltd
Darwin Discovery Ltd
Doutors Réassurance SA
Edev Sàrl
Element Genomics Inc.
Engage Therapeutics, Inc.
Show more

UCB Revenue Breakdown

Embed Graph

UCB revenue breakdown by business segment: 94.7% from NET SALES and 5.3% from Other

UCB Cybersecurity Score

Cybersecurity ratingPremium dataset

D

68/100

SecurityScorecard logo

UCB Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

60-79

out of 100

CSRHub logo

UCB Online and Social Media Presence

Embed Graph

UCB Company Culture

  • Overall Culture

    D

    59/100

  • CEO Rating

    F

    33/100

  • Compensation

    A+

    100/100

Learn more on Comparably

UCB News and Updates

UCB Showcases Strength of Broad Neurology Portfolio at 74th American Academy of Neurology (AAN) Annual Meeting

Scientific presentations illustrate UCB's commitment to addressing unmet needs of people living with a broad range of serious neurological diseases New data focused on epilepsy and Parkinson's disease (PD), including real-world use of BRIVIACT® (brivaracetam) CV, long-term use of...

UCB SA/NV - CONVENING NOTICE TO THE GENERAL MEETING OF SHAREHOLDERS 2022

*** Unofficial English translation – For convenience purposes only ***

BrightInsight and UCB Partner to Build Digital Care Solutions for Rare Diseases

UCB’s Digital Care Solutions for Myasthenia Gravis to be Built on the BrightInsight Platform UCB’s Digital Care Solutions for Myasthenia Gravis to be Built on the BrightInsight Platform

UCB to buy U.S. biopharmaceutical Zogenix in $1.9 billion deal

UCB to buy U.S. biopharmaceutical Zogenix in $1.9 billion deal

UCB to Buy Epilepsy Drugmaker Zogenix for Up to $1.9 Billion

UCB to Buy Seizure Drugmaker Zogenix for Up to $1.9 Billion

UCB announces positive Phase 3 results for rozanolixizumab in generalized myasthenia gravis

BRUSSELS, Dec. 10, 2021 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced positive topline results from the Phase 3 MycarinG study1 evaluating rozanolixizumab, a subcutaneously (SC) infused monoclonal antibody targeting the neonatal Fc receptor (FcRn), versus...
Show more

UCB Blogs

UCB announces positive data in myasthenia gravis with zilucoplan phase 3 study results

UCB announces positive data in myasthenia gravis with zilucoplan phase 3 study results Migration Fri 04/02/2022 - 06:00 UCB announces positive data in myasthenia gravis with zilucoplan phase 3 study results Positive…

Transparency notification FMR LLC.

Transparency notification FMR LLC. Migration Wed 02/02/2022 - 19:00 Transparency notification FMR LLC. Notification referring to situation on 27 January 2022 Threshold crossed: 5% Latest holding: 4.98%  …

UCB Receives Positive CHMP Opinion Recommending Approval of BRIVIACT[®] (brivaracetam) and VIMPAT[®] (lacosamide) in the EU for Partial-Onset Seizures in Pediatric Patients From Two to Four Years

UCB Receives Positive CHMP Opinion Recommending Approval of BRIVIACT[®] (brivaracetam) and VIMPAT[®] (lacosamide) in the EU for Partial-Onset Seizures in Pediatric Patients From Two to Four Years Migration Wed 02/02/2022 - 06:00 UCB Receives Positive CHMP Opin…

UCB Commences Tender Offer to Acquire Zogenix, Inc.

UCB Commences Tender Offer to Acquire Zogenix, Inc. Migration Tue 01/02/2022 - 17:00 UCB Commences Tender Offer to Acquire Zogenix, Inc. Brussels (Belgium) 1 February 2022, 18:00 CET – UCB (Euronext: UCB) is commenci…

BIMZELX[®] (bimekizumab) Approved in Japan for the Treatment of Plaque Psoriasis, Generalized Pustular Psoriasis and Psoriatic Erythroderma

BIMZELX[®] (bimekizumab) Approved in Japan for the Treatment of Plaque Psoriasis, Generalized Pustular Psoriasis and Psoriatic Erythroderma Migration Mon 24/01/2022 - 06:00 BIMZELX[®] (bimekizumab) Approved in Japan for the Treatment of Plaque Psoriasis, Gener…

Positive Top-Line Results for BIMZELX[®]▼(bimekizumab) in Second Phase 3 Psoriatic Arthritis Study

Positive Top-Line Results for BIMZELX[®]▼(bimekizumab) in Second Phase 3 Psoriatic Arthritis Study Migration Fri 21/01/2022 - 06:00 Positive Top-Line Results for BIMZELX[®]▼(bimekizumab) in Second Phase 3 Psoriatic Arthritis Study …
Show more

UCB Frequently Asked Questions

  • When was UCB founded?

    UCB was founded in 1928.

  • Who are UCB key executives?

    UCB's key executives are Jean-Christophe Tellier, Kirsten Lund-Jurgensen and Dhavalkumar Patel.

  • How many employees does UCB have?

    UCB has 7,600 employees.

  • What is UCB revenue?

    Latest UCB annual revenue is €5.5 b.

  • What is UCB revenue per employee?

    Latest UCB revenue per employee is €719.9 k.

  • Who are UCB competitors?

    Competitors of UCB include Jazz Pharmaceuticals, Lundbeck and Amarin.

  • Where is UCB headquarters?

    UCB headquarters is located at 60 Allée de la Recherche, Anderlecht.

  • Where are UCB offices?

    UCB has offices in Anderlecht, Braine-l'Alleud, Raleigh, Smyrna and in 36 other locations.

  • How many offices does UCB have?

    UCB has 40 offices.